DK1616183T3 - Fremgangsmåde til påvisning af neurologiske forstyrrelser - Google Patents

Fremgangsmåde til påvisning af neurologiske forstyrrelser

Info

Publication number
DK1616183T3
DK1616183T3 DK04758140.0T DK04758140T DK1616183T3 DK 1616183 T3 DK1616183 T3 DK 1616183T3 DK 04758140 T DK04758140 T DK 04758140T DK 1616183 T3 DK1616183 T3 DK 1616183T3
Authority
DK
Denmark
Prior art keywords
methods
neurological disorder
amyloid peptide
related neurological
detecting
Prior art date
Application number
DK04758140.0T
Other languages
English (en)
Inventor
Jorge J Palop
Lennart Mucke
Original Assignee
David Gladstone Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David Gladstone Inst filed Critical David Gladstone Inst
Application granted granted Critical
Publication of DK1616183T3 publication Critical patent/DK1616183T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/851—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from growth factors; from growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analyzing Materials By The Use Of Ultrasonic Waves (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
DK04758140.0T 2003-03-24 2004-03-24 Fremgangsmåde til påvisning af neurologiske forstyrrelser DK1616183T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45720003P 2003-03-24 2003-03-24
PCT/US2004/009216 WO2004084711A2 (en) 2003-03-24 2004-03-24 Methods of detecting neurological disorders

Publications (1)

Publication Number Publication Date
DK1616183T3 true DK1616183T3 (da) 2011-02-14

Family

ID=33098211

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04758140.0T DK1616183T3 (da) 2003-03-24 2004-03-24 Fremgangsmåde til påvisning af neurologiske forstyrrelser

Country Status (8)

Country Link
US (1) US7297836B2 (da)
EP (1) EP1616183B1 (da)
JP (1) JP5054972B2 (da)
AT (1) ATE487942T1 (da)
CA (1) CA2517452C (da)
DE (1) DE602004029998D1 (da)
DK (1) DK1616183T3 (da)
WO (1) WO2004084711A2 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5153114B2 (ja) 2006-10-12 2013-02-27 知宏 千葉 新規のアルツハイマー病検出方法
WO2018094218A1 (en) * 2016-11-17 2018-05-24 Children's Medical Center Corporation Therapeutic modulation of c-fos in the eye
JP7466886B2 (ja) * 2019-06-21 2024-04-15 学校法人帝京大学 孵化後の鳥類ヒナの学習特性を利用した認知機能向上薬のスクリーニング方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0833901A1 (en) * 1995-06-07 1998-04-08 Athena Neurosciences, Inc. Method for identifying alzheimer's disease therapeutics using transgenic animal models
US5767337A (en) 1995-07-31 1998-06-16 Duke University Creation of human apolipoprotein E isoform specific transgenic mice in apolipoprotein deficient "knockout" mice
US6455757B1 (en) 1997-10-08 2002-09-24 The Regents Of The University Of California Transgenic mice expressing human APP and TGF-β demonstrate cerebrovascular amyloid deposits
US6175057B1 (en) 1997-10-08 2001-01-16 The Regents Of The University Of California Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy
US6046381A (en) 1998-04-30 2000-04-04 The Regents Of The University Of California Apolipoprotein E transgenic mice and assay methods

Also Published As

Publication number Publication date
DE602004029998D1 (de) 2010-12-23
US20040229258A1 (en) 2004-11-18
CA2517452A1 (en) 2004-10-07
EP1616183A4 (en) 2006-07-19
EP1616183A2 (en) 2006-01-18
ATE487942T1 (de) 2010-11-15
JP2006521115A (ja) 2006-09-21
US7297836B2 (en) 2007-11-20
CA2517452C (en) 2012-03-13
EP1616183B1 (en) 2010-11-10
JP5054972B2 (ja) 2012-10-24
WO2004084711A2 (en) 2004-10-07
WO2004084711A3 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
NL301145I2 (nl) Tirbanibulin
WO2003071927A3 (en) Diagnostics and therapeutics for macular degeneration-related disorders
DK1838355T3 (da) Forbedrede quenching-fremgangsmåder til erytrocyt-inaktiveringsfremgangsmåde
WO2006015087A3 (en) Thalamic stimulation device
WO2007044763A3 (en) System and method for detecting fraudulent transactions
TW200716673A (en) Use of TNF &ahr; inhibitor for treatment of erosive polyarthritis
DE602005014134D1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
BR0300035B1 (pt) sistema para otimizar uma prescriÇço para um tratamento refrativo.
NO20032944D0 (no) Styringssystem for kjemisk injisering samt fremgangsmåte for kjemisk injisering i flere brönner
ATE549416T1 (de) Verfahren und zusammensetzungen zum nachweis von autoimmunkrankheiten
SG126114A1 (en) Method and system for improving quality in a service industry
ITMI20051058A1 (it) "metodo e sistema per fabbricare componenti mediante elettroerosione"
TW200609559A (en) Contact lenses and methods for their design
BR0309292B1 (pt) mÉtodo para lixiviamento de ouro.
WO2004070025A3 (en) Novel goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders
WO2004081521A3 (en) Methods for direct detection of individual methotrexate metabolites
DK1616183T3 (da) Fremgangsmåde til påvisning af neurologiske forstyrrelser
MXPA05008793A (es) Metodos para la prediccion de posibilidad de suicidio durante el tratamiento.
WO2005019475A3 (en) Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
NO20041393L (no) Borefluid, samt apparat og fremgangsmate
ATE527875T1 (de) Erhöhung des ölgehalts in brassica-pflanzen
WO2007075318A3 (en) Agents that reduce apoe-induced impairment of mitochondria and methods of use thereof
ITMI20030350A1 (it) Metodo e sistema per la predizione di terremoti.
EP1474434A4 (en) THE EAAT2 PROMOTER AND ITS USE
DK1556489T3 (da) Farmaceutisk sammensætning til fremstilling af et lægemiddel til behandling og/eller forebyggelse af en patologi i forbindelse med obsessiv-kompulsiv forstyrrelse eller obesitet